TORONTO, April 4, 2023 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I (FAV LS Fund I), a multimillion-dollar life science fund with a focus on supporting research developed…


Previous articleAlgernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
Next articleAlgernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study